Easton Pharmaceuticals and BMV Medica Announce Placing Initial Order for Both of Its Patented Women's Health Diagnostic Products

Easton Pharmaceuticals Inc. (OTCPINK:EAPH) together with its partner BMV Medica, announced it has placed an initial order for both the vaginal discharge diagnsostic test (VS-Sense) and the amniotic fluid leak test (AmnioSense) from manufacturer CommonSense of Israel, with delivery expected in late March, to coincide with a planned April launch.
According to the company press release:

This first-order of the CommonSense products is for the Mexican launch with the total number of units ordered at 230,000, – 90,000 units of the VS-Sense and 140,000 units of the AmnioSense, enough product for launch and three-six months of sales. Easton/BMV anticipate to file the regulatory dossier for VS-Sense early this week, and expect approval prior to the expected delivery date of this first order in late March. The AmnioSense diagnostic test as well as the Gynofit bacterial vaginosis treatment are already approved in Mexico through third-party consultants. BMV is in the process of having the Marketing Approvals (registrations) transferred to BMV Medica, so all three products can be launched at the same time. Easton/BMV will be placing an initial order for Gynofit with the Swiss manufacturer over the next few weeks.

Dr. Jose Tiran Saucedo as the Founding Member of Easton Pharma’s Medical/ Scientific Advisory Board commented:

I am very excited to be part of the program for these soon-to-be-launched women’s health and treatment products in the hope of providing to Latin American women the same choices they have in the US and Europe. We have a huge unmet medical need in Latin America for these kind of alternative diagnostic and treatment products. The vaginal discharge diagnostic test will facilitate a woman’s ability to determine the causative agent; the natural lactic acid treatment gel will provide a new, non-toxic treatment option, and put Latin American women on a par with North American and European women. The professional version of this diagnostic test will also enable the gynecologist to increase the accuracy in the differential diagnosis of vaginal discharge, right in the gynecologist’s office, something currently lacking in Latin America. The natural lactic acid gel treatment expected to launch in parallel with the diagnostic will be offered to women who test positive for bacterial infection and is a significant treatment option advance since it could obviate the need for potential use of antibiotics and further presence of bacterial resistance, so this is a promising and exciting development for the future of women’s health.

Click here to view the full press release.